UroGen Pharma Reports $27.5M Revenue in Q3 2025, Net Loss Increases to $33.3M

UroGen Pharma Ltd. reported a revenue of $27.5 million for the third quarter of 2025, marking a 9% increase from $25.2 million in the same period of 2024. For the nine months ending September 30, 2025, total revenue reached $72.0 million, up from $65.8 million year-over-year. The growth in revenue is attributed to increased sales of its flagship product, Jelmyto, and the recent launch of Zusduri, which contributed approximately $1.8 million in sales during the quarter. Despite the revenue increase, UroGen reported a net loss of $33.3 million for the quarter, compared to a loss of $23.7 million in the prior year, primarily due to rising operating expenses.

The company's operating expenses surged to $51.6 million in Q3 2025, up from $40.3 million in Q3 2024. This increase was driven by higher research and development costs, which rose to $14.0 million from $11.4 million, and selling and marketing expenses, which increased to $23.7 million from $17.8 million. The rise in expenses reflects UroGen's strategic focus on expanding its commercial operations and advancing its clinical trials, particularly for UGN-103 and UGN-104.

UroGen's balance sheet as of September 30, 2025, showed total assets of $185.0 million, a decrease from $285.7 million at the end of 2024. The decline in assets was primarily due to a reduction in cash and cash equivalents, which fell to $90.0 million from $172.0 million. The company also reported an accumulated deficit of $933.4 million, up from $806.2 million at the end of the previous fiscal year. UroGen's total liabilities increased to $300.5 million, compared to $294.5 million at the end of 2024, largely due to the ongoing financing obligations related to its prepaid forward agreement with RTW Investments.

In terms of operational developments, UroGen has expanded its product offerings with the FDA approval of Zusduri in June 2025, which is aimed at treating recurrent low-grade intermediate risk non-muscle invasive bladder cancer. The company has initiated a strategic marketing campaign to promote Zusduri, leveraging its existing sales force and medical science liaisons to enhance product adoption. UroGen's workforce has grown to approximately 130 employees, reflecting its commitment to expanding its commercial capabilities.

Looking ahead, UroGen anticipates continued investment in research and development, particularly for its pipeline products, and expects to incur further losses as it seeks to establish a foothold in the urothelial cancer treatment market. The company believes it has sufficient cash reserves to fund operations for at least the next year, but acknowledges the need for additional capital to support its growth strategy and product commercialization efforts.